MELANOMA CRITICAL DEBATES - PART 2 pdf
MELANOMA CRITICAL DEBATES - PART 2 pdf
... 78/131 2. 27 (1.3–4.1) ≠ Graham et al. [ 42] USA 1974–80 404/ 521 2. 2 (1 .2 4.1) ≠ Herzfeld et al. [43] USA 1977–79 324 /415 2. 58 (1. 42 4.69) ≠ Beitner et al. [44] Sweden 1978–83 523 /505 1.8 (1 .2 2. 7) ... min 25 20 1.44 0.75 2. 82 ≥ 180 min 39 18 2. 50 1.34–4.80 Test for linear trend in males: P= 0.00 12 Females Never used 22 2 25 6 1.00‡ — < 180 min 39 39 1.17 0.70–1.95 ≥...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 1 ppt
... Martin [DNLM: 1. Melanoma. QZ 20 0 C437 20 01] RC280.M37 C48 20 01 616.99¢477—dc21 20 0103 520 2 ISBN 0-6 3 2- 0 577 2- 6 A catalogue record for this title is available from the British Library Set in 10/13 1 / 2 Sabon ... Australia 26 7 1.1 (0.7–1.8) Osterlind et al. [20 ] Denmark 474 1.8 (1 .2 2. 5) Beitner et al. [21 ] Sweden 523 1.8 (1 .2 2. 6) Dubin et al. [22 ] USA 29 0 1...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 3 pptx
... RJH. Photosensitisation of guanine-specific DNA damage by 2- phenylbenzimidazole and the sunscreen agent 2- phenyl- benzimidazole-5-sulfonic acid. Chem Res Toxicol 1999; 12: 38–45. ized by sensitivity ... value with respect to melanoma occurrence. • It is not uncommon to find atypical naevi and even melanoma in non- mutation carriers in high-risk melanoma kindreds [22 ,26 ,27 ]. This ma...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 4 pps
... 1159– 62. 15 Martin HM, Birkin AJ, Theaker JM. Malignant melanoma re-excision specimens: how many blocks? Histopathology 1998; 32: 3 62 7. 16 Kirkham N. What is there to find in malignant melanoma re-excision specimens? ... for the regular follow-up of selected high-risk individuals re- sults in thinner melanomas being diagnosed, as concluded from a Dutch study on high-risk patients from...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 5 ppt
... cases. Br J Plast Surg 19 92; 45: 27 5–8. 31 Park KGM, Blessing K, Kernohan NM. Surgical aspects of subungual malignant melanomas. Ann Surg 19 92; 21 6: 6 92 5. 32 Heaton KN, El-Naggar A, Ensign LG, 11: ... of Malignant Melanoma. Basel: Karger, 1996: 31– 42. 23 Howell JB, Cockerell CJ. Melanoma self- examination day: Melanoma Monday, May 1, 1995. J Am Acad Dermatol 1996; 34: 837–8....
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 6 pot
... the detection of melanoma metastases. Ann Surg 1998; 22 7: 764–9; discussion 769–71. 35 Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2- [ 18F ] -2 -deoxy- D-glucose positron emission ... of 2- uoro -2 - deoxyglucose (FDG)-PET scanning was re- ported for detection of melanoma metastases [33,34]. Although access to PET is at present limited, it is a promisin...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 7 ppt
... set- ting in high-risk melanoma patients. Interleukin 2 Interleukin 2 (IL -2 ) has modest activity in stage IV melanoma but so far has not been evaluated widely in the adjuvant setting in melanoma. ... [47] 20 55 McClay et al. [48] 20 50 Richards et al. [49] 20 55 Saba et al. [50] 14 29 Fierro et al. [51] 32 43 Reintgen & Saba [ 52] 47 46 Lattanzi et al. [53] 42 54 (with...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 8 pot
... A3, A24, B37, B44, DR11, DR13 MAGE-4A 55 11 22 MAGE-6 [63] 89 ? ? MAGE- 12 89 ? ? MAGE-C1 [36] 37 53 BAGE 22 Cw1601 GAGE [63] 24 Cw6 LAGE [28 ] 50 SSX -2 [30] 43 NY-ESO-1 [29 ] 20 –40 A2, A31 DAM [27 ] ... report 1997 [55] Response rate (%) IL -2 only 14.9 7.5 12 4 IL -2 + chemotherapy 23 .0 9.9 13 8 IL -2 + IFN-a 20 .8 10.5 24 14 IL -2 + chemotherapy+IFN-a 44.8 11.4 22 12 *Pati...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 9 pps
... STRATEGIES FOR THE TREATMENT OF MELANOMA 24 7 et al. bcl -2 Antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4 (2) : 23 2–4. 15 Jansen B, Wacheck V, Heere-Ress E, et al. A Phase ... cuta- neous deposits. Hornsey [5] found responses in 21 % (6 /28 ) patients at 2 3 Gy, 55% (16 /29 ) with 3–4Gy and 54% (20 /37) with 4–8Gy. Overgaard [6] re- ported 35% (6/17)...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 10 pptx
... 197, 198 20 1, 23 8, 24 2 trials in stage III 198 20 0, 199 high-dose 199 low-dose 199 20 0 trials in stage II 20 0–1 g-interferon 197, 23 3, 23 4, 24 3 interleukins IL -2 195, 197, 22 2, 23 8, 24 3 IL-4 24 3 IL-10 ... effectiveness 22 0 vaccinia melanoma cell lysates (VMCL) 21 4, 22 0, 22 1 vascular endothelial growth factor (VEGF) 22 2, 22 3, 23 9 VCAM-1 22 2 VEGFR -2...
Ngày tải lên: 09/08/2014, 15:20